Is Cognition Therapeutics, Inc. (CGTX) a Buy, Sell, or Hold?
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$1.01 USD
-$0.01 (-0.98%)
- Volume
- 1.3M
- Average Volume
- 1.57M
- Market Capitalization
- $74.32M
- P/E Ratio
- -3.85
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $3.83
- Year Low
- $0.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.92
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lisa Ricciardi |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CGTX |
| CUSIP | 19243B102 |
| CIK | 0001455365 |
| Web | https://www.cogrx.com |
| Phone | 412 481 2210 |
| Currency | USD |
| Employees | 14 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.92 |
| Quick Ratio | 5.92 |
| Cash Ratio | 5.14 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.23 |
| Price / Cash Flow | -3.67 |
| Price / Book | 3.01 |
Price Target and Rating
| Average Stock Price Forecast | $3.00 |
| High Stock Price Forecast | $3.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -66.33% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.32 |
| Trailing P/E Ratio | -3.85 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-23.49M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -72.68% |
| Return on Assets | -54.17% |
Financials Score
| AltmanZ Score | -1.44 |
| Piotroski Score | 1.00 |
| Working Capital | 29.76M |
| Total Assets | 36.14M |
| Ebit | -19.56M |
| Market Cap | 75.05M |
| Total Liabilities | 6.23M |
Poll Results
About Cognition Therapeutics, Inc. (NASDAQ:CGTX) Stock
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also ... includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
2026-07-13 07:30:00
PURCHASE, N. Y. , July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B.
2026-07-13 07:30:00
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company's ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain
2026-06-26 10:07:20
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.
2026-06-24 07:30:00
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -
2026-06-16 07:30:00
PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.
Cognition Therapeutics Participating in Upcoming Investor Conferences
2026-06-01 07:30:00
PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company's plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition's website.
2026-05-21 07:30:00
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026.
2026-05-14 07:30:00
PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic donation has been received from a participant in the ongoing expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach, FL.
Frequently Asked Questions
-
What is the current Cognition Therapeutics, Inc. (CGTX) stock price?
-
Cognition Therapeutics, Inc.(NASDAQ:CGTX) stock price is $1.01 in the last trading session. During the trading session, CGTX stock reached the peak price of $3.83 while $0.55 was the lowest point it dropped to. The percentage change in CGTX stock occurred in the recent session was --0.98% while the dollar amount for the price change in CGTX stock was -$-0.01.
-
CGTX's industry and sector of operation?
-
The NASDAQ listed CGTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CGTX?
-
Bobby Horn | Corporate Controller
Anthony O. Caggiano | Chief Medical Officer
Steven A. Weissman | Vice President & Head of CMC
John Brendan Doyle | Chief Financial Officer
Anita Cornet | Head of Quality -
How many employees does CGTX have?
-
Number of CGTX employees currently stands at 14. CGTX operates from 2500 Westchester Avenue, Purchase, NY 10577, US.
-
Link for CGTX official website?
-
Official Website of CGTX is: https://www.cogrx.com
-
How do I contact CGTX?
-
CGTX could be contacted at phone #412 481 2210 and can also be accessed through its website. CGTX operates from 2500 Westchester Avenue, Purchase, NY 10577, US.
-
How many shares of CGTX are traded daily?
-
The average number of CGTX shares traded daily for last 3 months was 1.57M.
-
What is the market cap of CGTX currently?
-
The market value of CGTX currently stands at $74.32M with its latest stock price at $1.01